On August 26, 2026 BioInvent International AB reported Interim report January – June 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"During the second quarter, both of our lead programs generated clinical data that further strengthened their competitive positioning. BI-1808 (anti-TNFR2) reported new results in two distinct indications, recurrent ovarian cancer and cutaneous T-cell lymphoma (CTCL), each a setting where patients have few effective options after standard treatment fails. BI-1206 (anti-FcγRIIB) reported triplet combination data in relapsed/refractory non-Hodgkin’s lymphoma (NHL) that compares favorably with recently approved regimens. We presented these results at ASCO (Free ASCO Whitepaper) and EHA (Free EHA Whitepaper) and discussed them directly with the clinical community through two KOL events." – Martin Welschof, CEO of BioInvent.
EVENTS IN THE SECOND QUARTER
BioInvent revealed solid data for the BI-1808 and KEYTRUDA (pembrolizumab) combination (ASCO 2026):
24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA — multiplying by three the historical KEYTRUDA single agent activity of 8% in KEYNOTE-100 (2019) (R)
BI-1808 showcased strong activity and immune activation data as single agent and in combination with KEYTRUDA in advanced CTCL (EHA 2026)
BI-1206 triplet combination with rituximab and acalabrutinib achieved 83% response rate in refractory NHL with improved safety vs. standard of care (EHA 2026)
Two successful KOL events showcasing the positive ASCO (Free ASCO Whitepaper) and EHA (Free EHA Whitepaper) data for BI-1808 and BI-1206
EVENTS AFTER THE END OF THE PERIOD
BI-1808 received FDA Fast Track Designation for the treatment of ovarian cancer
BioInvent’s BI-1808 abstract from Modest to Meaningful in platinum-resistant ovarian cancer accepted for poster presentation at ESMO (Free ESMO Whitepaper) 2026
BioInvent published two scientific papers in peer-reviewed journals. One in Cancer Research: "Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Employ Distinct Modes of Action to Induce Antitumor Immunity" and one in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models
(R)= Regulatory event
FINANCIAL INFORMATION
Second quarter 2026
Net sales SEK 12.8 (198.1) million.
Profit/loss after tax SEK -122.9 (38.8) million.
Profit/loss after tax per share before and after dilution SEK -1.87 (0.59)
Cash flow from operating activities SEK -112.0 (66.8) million.
January – June 2026
Net sales SEK 26.2 (220.2) million.
Profit/loss after tax SEK -242.1 (-77.8) million.
Profit/loss after tax per share before and after dilution SEK -3.68 (-1.18)
Cash flow from operating activities SEK -244.8 (-53.2) million.
Liquid funds and current investments as of June 30, 2026: SEK 340.8 (797.5) million.
The complete interim report is available for download below and on the company’s website under Financial reports.
(Press release, BioInvent, AUG 26, 2026, https://www.bioinvent.com/en/press/bioinvent-international-ab-interim-report-january-june-2026-2477090 [SID1234670361])